Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
06-08 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
06-08 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
19 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/19/3083995/0/en/Phase-II-Data-in-Treatment-Na%C3%AFve-Paroxysmal-Nocturnal-Hemoglobinuria-PNH-Patients-Ruxoprubart-Demonstrates-Best-in-Class-Efficacy-as-Monotherapy.html
24 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/24/3031279/0/en/United-States-FDA-Approves-NM8074-Ruxoprubart-IND-for-Treating-Dermatomyositis-DM-A-Chronic-Inflammatory-Disorder-of-the-Skin.html
17 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/17/2899645/0/en/FDA-Approves-Phase-II-Clinical-Trial-for-Ruxoprubart-in-ANCA-Associated-Vasculitis-AAV-a-Chronic-Rare-Disease-in-Nephrology.html
15 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/15/2862778/0/en/The-United-States-FDA-Awards-Orphan-Drug-Designation-ODD-to-NM5072-for-Treating-Paroxysmal-Nocturnal-Hemoglobinuria-PNH.html
12 Feb 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/02/12/2827525/0/en/Ruxoprubart-NM8074-Scores-FDA-Orphan-Drug-Designation-for-Paroxysmal-Nocturnal-Hemoglobinuria-PNH-Treatment.html
08 Jan 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/01/08/2805440/0/en/USAN-Approves-Generic-Name-Ruxoprubart-for-NM8074-an-Antibody-Therapy-focused-on-Complement-Mediated-Diseases.html
ABOUT THIS PAGE